In Peru, there is an internal confrontation between ministries due to the data protection provisions of the TPP. The Ministry of Health opposes to the extension on data protection due to the effects than it can have on access over medicines for Peruvians, as many international organizations such as Medicos Sin Fronteras have claimed. Nonetheless, the Ministry of Commerce, in a document published puts this statement in doubt. The document contains 105 questions about TPP. Regarding access to medicine the document raises a question: will the TPP affect public health? Then the document states that the same concern was made during the Peru-U.S. FTA negotiation, but that to the moment those concerns have not been rejected or accepted by the Ministry of Commerce.
This post contains a brief summary of, and excerpt from, a report published by the Third World Network. Click here for the full report. (eds.)
This document summarises some of the ways in which the Trans-Pacific Partnership Agreement (TPP) can harm human rights. The analysis below only examines the impact on recommendations and comments by United Nations (UN) Special Procedures mandate-holders and other United Nations human rights bodies,a so there are other human rights which are likely to be adversely affected by the TPP which are not covered here.
FOR IMMEDIATE RELEASE | CONTACT:
Nicole L’Esperance (Blumenauer), 202-225-4811
Aaron Hunter (Davis), 202-225-1686
Patrick Malone (Himes), 202- 225-5541
Washington, DC – As Trans-Pacific Partnership (TPP) negotiators meet in Hawaii, Representatives Earl Blumenauer (OR-03), Susan Davis (CA-53), Jim Himes (CT-04), and other Democratic members of the U.S. House of Representatives who recently voted to grant President Obama Trade Promotion Authority (TPA) urged U.S. Trade Representative (USTR) Michael Froman to ensure Intellectual Property (IP) provisions in the TPP protect timely and affordable access to medicines.
Dear Ambassador Froman: All consumers are users of intellectual property. The average American interacts with hundreds, if not thousands, of IP-protected products and goods each day. The Trans-Pacific Partnership must not weaken or otherwise disrupt the protections afforded to American consumers.
The United States is a global leader in intellectual property, not only because of the rights enjoyed by creators of knowledge goods, but also because of those rights granted to consumers. Preserving these rights must be central to any trade negotiation.
The following is an excerpt from the executive summary of a forthcoming paper. The paper was written under an IISD project funded under the Knowledge Partnership Programme of DFID India and IPE Global Pvt Ltd. The views are strictly those of the authors.
The report addresses recent developments in the area of intellectual property rights (IPRs) since the adoption of the TRIPS Agreement (1994) with particular emphasis on trends in preferential trade agreements (PTAs) and plurilateral initiatives such as the Trans-Pacific Partnership Agreement (TPP), ACTA and the new agenda of the European Union (EU) on intellectual property.
[Médecins Sans Frontières press release, Link] At the International AIDS Society (IAS) Conference today, the international medical humanitarian organisation Doctors Without Borders/Médecins Sans Frontières (MSF) warned that middle-income countries (MICs), which will be home to 70% of people living with HIV by 2020, face increasing threats to their ability to access affordable generic medicines, which are crucial to countries’ ability to reach the global UNAIDS 90/90/90* targets.
Inside U.S. Trade reports that USTR has “effectively wrapped up” negotiations with Vietnam and Singapore and “will seek to bring TPP ‘to some kind of a conclusion’ when ministers meet later this month in Hawaii.” Froman has delivered an “ultimatum” to Malaysia.
Reps. Schakowsky and DeLauro joined MSF, AARP and others at a press briefing on IP and Access to Medicines. Rep. Schakowsky told the press that “What is clear is that it is U.S. negotiators who are pushing to tilt the balance between intellectual property rights and public health even more toward the brand-name drug companies.”
This post presents data comparing branded antiretroviral medicine prices in countries which have entered into free trade agreements with the U.S. containing TRIPS-Plus intellectual property obligations, to the prices for the same drugs in other countries. According to publicly available data from the World Health Organization’s Global Price Reporting Mechanism (GPRM), prices of branded antiretrovirals negotiated by large institutional purchasers (like UNITAID and the Clinton Foundation) were more than twice as high between 2004 and 2014 when the sale took place in countries with U.S. FTAs. If one controls for per capita income, inclusion in international HIV/AIDS treatment guidelines, and the year of purchase, the average difference between the negotiated price of branded drugs in countries with and without FTAs in force is 57%. The price differences vary greatly by drug.
[The Commons Network, Link, (CC-BY] How can we address the high prices of medicines that are straining health budgets? How can openly sharing green knowledge help an agreement at the climate change talks in Paris this year? How could TTIP further privatize knowledge and what can we do about it? What does it mean to say the Internet belongs to everyone?
The Commons perspective sheds light on the democratic governance of knowledge for the common good and identifies knowledge as a shared resource that is a collective responsibility. It emphasizes equitable access to knowledge resources such as health-care, the need to prioritize ecological sustainability in knowledge policy and to promote participation in the management of an open and democratic Internet.
[Reposted from EFF Deeplinks Blog, Link, (CC-BY)] A draft of the Trans-Pacific Partnership‘s “Intellectual Property” chapter from May 11, 2015 hasrecently been leaked to journalists. This is the fourth leak of the chapter following earlier drafts of October 2014, August 2013, and February 2011. The latest leak is not available online and we don’t have a copy of it—but we have been briefed on its contents.
Inside U.S. Trade reports that Trade Ministers have scheduled Trans Pacific Partnership Ministerial for the end of July in Hawaii. Chief negotiators will meet prior to the Ministerial to try to iron out remaining areas of disagreement.
Jiji press reports that there are six unresolved areas where “negotiations are not proceeding smoothly.” Data exclusivity for biologics is one such area. The story quotes a Japanese negotiator saying “Unless Washington shortens the requested protection period, there is little chance of an agreement.”
[Patralekha Chatterjee for IP Watch, Link (CC-BY-NC-SA)] The Trans-Pacific Partnership (TPP), part of US President Barack Obama’s promised pivot to Asia, has stirred up a hornet’s nest on the ethics of trying to hammer out a trade deal in secrecy. But it is not the only one. A proposed trade agreement in Asia, the Regional Comprehensive Economic Partnership (RCEP), is facing the same hiccups and flak.